Bempedoic Acid in Secondary Prevention
Open Access
- 6 August 2024
- journal article
- editorial
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 19, 100715
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Effect of bempedoic acid on mortality and cardiovascular events in primary and secondary prevention: A post-hoc analysis of the CLEAR-outcomes trialInternational Journal of Cardiology, 2024
- Impact of Bempedoic Acid on Total Cardiovascular EventsJAMA Cardiology, 2024
- Redefining Cardiovascular Risk Assessment as a SpectrumJACC, 2024
- Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trialThe Lancet Diabetes & Endocrinology, 2023
- Bempedoic Acid for High-Risk Primary Prevention of Cardiovascular DiseaseJAMA, 2023
- Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant PatientsJAMA, 2023
- Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trialThe Lancet Diabetes & Endocrinology, 2019
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood CholesterolJACC, 2019
- Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trialsThe Lancet Diabetes & Endocrinology, 2016
- The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trialThe Lancet, 2011